{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:19:34Z","timestamp":1793755174482,"version":"4.6.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"\n Importance<\/jats:title>\n Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n\u2009=\u2009125), frontotemporal lobar degeneration (FTLD; n\u2009=\u2009198), or cognitively unimpaired (CU) at the time of evaluation (n\u2009=\u200916) were included.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n AD-related or FTLD-related clinical syndromes or CU.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110\/125 [88%]) and FTLD-related syndromes (45\/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82\/88 [93%] AD vs 13\/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30\/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg\/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg\/mL) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.05). Plasma p-tau217 concentrations were highest in atypical AD-related syndromes (mean [SD], 0.33 [0.02] pg\/mL), followed by typical late-onset amnestic syndromes (mean [SD], 0.27 [0.03] pg\/mL). FTLD-related syndromes with AD (mean [SD], 0.19 [0.02] pg\/mL) were higher compared to without (mean [SD], 0.07 [0.00] pg\/mL). Plasma p-tau217 detected AD neuropathology across syndromes (area under the receiver operating characteristic curve [AUC], 0.95; 95% CI, 0.93-0.97), with slightly better performance in AD-related syndromes (AUC, 0.98; 95% CI, 0.95-1.00) compared to FTLD-related syndromes (AUC, 0.89; 95% CI, 0.83-0.94). NfL and GFAP had lower performance for detecting AD (AUC, 0.73; 95% CI, 0.68-0.78 and AUC, 0.75; 95% CI, 0.67-0.80, respectively) and added little to no diagnostic value either alone or in combinations with p-tau217. The presence of AD in FTLD-related syndromes was associated with lower Mini-Mental State Examination score (mean [SD], \u22122.90 [1.09];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.05), worse performance on memory (mean [SD]\n z<\/jats:italic>\n score, \u22120.64 [0.32]), executive (mean [SD]\n z<\/jats:italic>\n score, \u22120.74 [0.19]), and visuospatial composites (mean [SD]\n z<\/jats:italic>\n score, \u22120.88 [0.37]) as well as increased rates of posterior cortical atrophy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.5017","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:01:33Z","timestamp":1739185293000},"page":"344","source":"Crossref","is-referenced-by-count":69,"title":["Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers"],"prefix":"10.1001","volume":"82","author":[{"given":"Lawren","family":"VandeVrede","sequence":"first","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Cho","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sanderson-Cimino","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fattin","family":"Wekselman","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Cobigo","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Gorno-Tempini","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary W.","family":"Heuer","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel H.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentina","family":"Lario Lago","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Leichter","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ljubenkov","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Perry","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Associate Editor, JAMA Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Rojas","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard J.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Saloner","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Staffaroni","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[{"name":"Neuroscience Biomarkers, Janssen Research & Development, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Spina","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Seeley","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea T.","family":"Grinberg","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Department of Pathology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmuth C.","family":"Kolb","sequence":"additional","affiliation":[{"name":"Neuroscience Biomarkers, Janssen Research & Development, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"noi240092r1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi240092r2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"noi240092r3","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"5","key":"noi240092r4","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"1","key":"noi240092r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","article-title":"Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults.","volume":"146","author":"Yu","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"1","key":"noi240092r6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","article-title":"Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.","volume":"17","author":"Murray","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"1","key":"noi240092r7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-023-02660-3","article-title":"Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study.","volume":"147","author":"Montoliu-Gaya","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"5","key":"noi240092r8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2023.0488","article-title":"Evaluation of plasma phosphorylated tau217 for differentiation between Alzheimer disease and frontotemporal lobar degeneration subtypes among patients with corticobasal syndrome.","volume":"80","author":"VandeVrede","year":"2023","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi240092r9","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awx254","article-title":"Clinicopathological correlations in behavioural variant frontotemporal dementia.","volume":"140","author":"Perry","year":"2017","journal-title":"Brain"},{"issue":"1","key":"noi240092r10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ana.26930","article-title":"Evaluating the effect of Alzheimer\u2019s disease-related biomarker change in corticobasal syndrome and progressive supranuclear palsy.","volume":"96","author":"Garcia-Cordero","year":"2024","journal-title":"Ann Neurol"},{"issue":"5","key":"noi240092r11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials.","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"9","key":"noi240092r12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis.","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi240092r13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi240092r14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1017\/S1355617721000813","article-title":"Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment.","volume":"28","author":"Asken","year":"2022","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"noi240092r15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration.","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"noi240092r16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41591-022-01942-9","article-title":"Temporal order of clinical and biomarker changes in familial frontotemporal dementia.","volume":"28","author":"Staffaroni","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"noi240092r17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"noi240092r18","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12434","article-title":"Operationalizing selection criteria for clinical trials in Alzheimer\u2019s disease: biomarker and clinical considerations.","volume":"9","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"noi240092r19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"Pt 9","key":"noi240092r20","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"11","key":"noi240092r21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants.","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"noi240092r22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria.","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"issue":"5","key":"noi240092r23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration.","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"8","key":"noi240092r24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy.","volume":"13","author":"Crutch","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240092r25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium.","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"noi240092r26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/alz.12033","article-title":"Utility of the global CDR plus NACC FTLD rating and development of scoring rules: data from the ARTFL\/LEFFTDS Consortium.","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240092r27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/alz.13454","article-title":"Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.","volume":"20","author":"Saloner","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240092r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach.","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"1","key":"noi240092r29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-008-0460-5","article-title":"Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.","volume":"117","author":"Mackenzie","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"3","key":"noi240092r30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.","volume":"9","author":"McKeith","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"noi240092r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103144","article-title":"Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling.","volume":"36","author":"Cobigo","year":"2022","journal-title":"Neuroimage Clin"},{"issue":"5","key":"noi240092r32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","article-title":"Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research.","volume":"11","author":"O\u2019Bryant","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240092r33","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12204","article-title":"Development and validation of a high-sensitivity assay for measuring p217+tau in plasma.","volume":"13","author":"Triana-Baltzer","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"noi240092r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: improved estimation and validation of optimal cutpoints in R.","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Softw"},{"issue":"4","key":"noi240092r35","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease.","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"2","key":"noi240092r36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","article-title":"Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals.","volume":"20","author":"Brum","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi240092r37","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u00df pathology in preclinical Alzheimer\u2019s disease.","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"noi240092r38","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u00df but not tau pathology in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"1","key":"noi240092r39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment.","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"noi240092r40","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12315","article-title":"Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.","volume":"14","author":"Windon","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"14","key":"noi240092r41","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","article-title":"Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort.","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"noi240092r42","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma A\u00df42\/A\u00df40, phosphorylated tau, and neurofilament light.","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2830013\/jamaneurology_vandevrede_2025_oi_240092_1743609759.1326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:01:06Z","timestamp":1744628466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2830013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.5017","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}